Kornimate/medical-research-clean huggingface dataset:
hot water immersion as a heat acclimation strategy in older adults

Conditions: Hyperthermia; Heat Exposure; Heat Stress; Thermoregulation; Aging

Summary: aging is associated with impairments in heat loss responses of skin blood flow and sweating leading to reductions in whole-body heat loss. consequently, older adults store more body heat and experience greater elevations in core temperature during heat exposure at rest and during exercise. this maladaptive response occurs in adults as young as 40 years of age. recently, heat acclimation associated with repeated bouts of exercise in the heat performed over 7 successive days has been shown to enhance whole-body heat loss in older adults, leading to a reduction in body heat storage. however, performing exercise in the heat may not be well tolerated or feasible for many older adults. passive heat acclimation, such as the use of warm-water immersion may be an effective, alternative method to enhance heat-loss capacity in older adults. thus, the following study aims to assess the effectiveness of a 7-day warm-water immersion (\~40°c) protocol in enhancing whole-body heat loss in older adults. warm-water immersion will consist of a one-hour immersion in warm water with core temperature clamped at 38.5°c. improvements in whole-body heat loss will be assessed during an incremental exercise protocol performed in dry heat (i.e., 40°c, \~15% relative humidity) prior to and following the 7-day passive heat acclimation protocol. the incremental exercise protocol will consist of three 30 minute exercise bouts performed at increasing fixed rates of metabolic heat production (i.e., 150, 200, and 250 w/m2), each separated by 15-minutes of recovery, with exception final recovery will be 1-hour in duration) performed in a direct calorimeter (a device that provides a precise measurement of the heat dissipated by the human body).


Eligibility criteria:
inclusion criteria: * elderly (60-80 years), non-smoking adults. * not engaged in regular physical activity (\>2 sessions/week for ≥20 minutes per session). * willing to provide informed consent. * healthy, no diagnosed health conditions. * body mass index (bmi) \<35 kg/m2. exclusion criteria: * heat adapted due to repeated exposure to hot environments within the last 3 weeks (use sauna, recent travel to hot climates, other).

Keywords: thermoregulation warm-water immersion heat acclimation aging
the inspiratory muscle activation pattern and training efficacy in patients with chronic obstructive pulmonary disease after acute exacerbation

Conditions: Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to assess the activation patterns of diaphragm and sternocleidomastoid (scm) muscle during different loaded inspiratory muscle performance in patients with copd after acute exacerbation. null hypothesis (h0): there is no significant difference between activation pattern of diaphragm and scm muscle during different loaded inspiratory muscle performance in patients with copd after acute exacerbation. alternative hypothesis (h1): there is significant difference between activation pattern of diaphragm and scm muscle during different loaded inspiratory muscle performance in patients with copd after acute exacerbation.

the prevalence of chronic obstructive pulmonary disease (copd) is 11.7% around the world, and it is expected to rise over the next 30 years. in taiwan, copd is estimated as the seventh leading cause of death in 2016, and has been gradually increasing in the past decades. copd has been long considered to be a disease state characterized by airflow limitation that are not fully reversible, leading to abnormalities in control of breathing, worsening of respiratory mechanics and pulmonary function. however, copd is no longer considered to affect only the lungs and airways, but also the rest of the body including decreases in respiratory and limb-muscle mass and function. when acute exacerbation occurs, lung function decreases rapidly. according to the previous studies, inspiratory muscle training (imt), can improve the strength and endurance of the diaphragm, reduce dyspnea and breathing pattern, thus increasing the capacity of activities tolerance in patients with copd. although more and more studies are focus on diaphragm weakness and the effect of imt in patients with copd, the efficacy and intensity of imt in patients with copd is still controversial and the clinical use is limited. whether increases intensity during imt would lead to improvements in contraction pattern of respiratory muscle remained unclear. therefore, the purpose of this study is to assess the activation patterns of diaphragm and sternocleidomastoid (scm) muscle during different loaded inspiratory muscle performance in patients with copd after acute exacerbation.

Eligibility criteria:
inclusion criteria: * age \> 20 years old * has been diagnosis of chronic obstructive pulmonary disease and experienced at least 2 times of acute exacerbation in recent 6 months * can cooperate with the measurements of this study exclusion criteria: * any clinical diagnosis that will influence the measurement, including any history of neuromyopathy * angina, acute myocardial infarction in the previous one month * pregnancy * participated in inspiratory muscle training program in the previous three months * any psychiatric or cognitive disorders, for example: mini-mental state examination (mmse) \< 24, that will disturb the communication and cooperation of the study
gray matters alzheimer's disease prevention intervention

Conditions: Alzheimer's Disease

Summary: this is a randomized controlled trial to develop and test the efficacy of a multi-domain lifestyle behavioral intervention designed to promote healthier lifestyle behaviors linked to lower alzheimer's disease risk among persons aged 40 to 64 years.

this is a randomized controlled trial to develop and test the efficacy of a multi-domain lifestyle behavioral intervention designed to promote healthier lifestyle behaviors linked to lower alzheimer's disease risk among persons aged 40 to 64 years. participants are randomized to treatment or control condition. the intervention, spanning a six month period, is an evidence-based health education program.

Eligibility criteria:
inclusion criteria: * age * residing or working in cache county utah * possessing smart phone or tablet exclusion criteria: * dementia * pregnancy * untreated chronic major depression or other psychiatric condition * body mass index \> 41 * heart or stroke in prior 6 weeks * active cancer treatment * unwillingness to seek medical help when serious condition identified at intake

Keywords: alzheimer's disease prevention lifestyle intervention
sleep and nocturnal enuresis: ambulatory polysomnographic study

Conditions: Nocturnal Enuresis; Polysomnography

Summary: full ambulatory polysomnography at home performed two nights in 30 healthy children and one night in 30 children with mono-symptomatic nocturnal enuresis (15 with polyuria and 15 without polyuria). the children will be aged 7-14 years of age. the sleep will be evaluated on sleep quality, number of periodic limb movements per hour, blood pressure and pulse, beat to beat variation by electrocardiography during sleep, respiration during sleep, nocturnal urine production, and enuresis episodes.

purpose and perspectives: the purpose of the study is to investigate the quality of sleep, the sleep architecture and the intra-individual variation from night to night in healthy children and children with mono-symptomatic nocturnal enuresis (mne) using full polysomnography at home. hypotheses: * there is large intra-individual night to night variation in sleep quality and architecture. * children with mne have different sleep architecture than healthy children when looking at sleep quality and arousals. * periodic limp movements at sleep is more frequent in children with mne than in healthy children. design: the study is a case-control study. materials and methods: the study will recruit 30 healthy children and 30 children with mne (15 with polyuria and 15 without polyuria) recruited from the childrens incontinence center at the department of pediatrics and adolescent medicine at aarhus university hospital. children of both sexes aged between 7 and 14 years of age will be enrolled. children and their parents will be informed about the study both verbally and in written. written informed consent from both parents must be obtained before the children can be enrolled in the study. the healthy children will go through two nights of full polysomnography to be able to view intra-individual changes. the children with mne will only have to do one night of polysomnography. primary parameters: * sleep quality * number of periodic limb movements per hour * blood pressure and pulse * beat to beat variation by electrocardiography during sleep * respiration during sleep * nocturnal urine production * enuresis episodes

Eligibility criteria:
inclusion criteria: * 7-14 years of age * normal objective evaluation including blood pressure * for healthy controls achieved continence both day and night before the age of 5. * for children with nocturnal enuresis at least 3 wet nights per week. * for children with enuresis clinical characteristics and at least one week of home recordings of nocturnal urine production and two days of full recording of fluid intake and urine production. exclusion criteria: * obstipation (according to rom iv criteria) * day incontinence or severe urgency * insomnia or known sleep disorders such as sleep walking, heavy snoring, night terrors or abnormal circadian rhythm. * present or former deceases in the urinary tract, liver or in the endocrinological system. * hypertension * treatment with medication at the time of the study * adhd, autism or other psychiatric disorders.
research on wireless brain implant system for general control of external devices

Conditions: Complete or Incomplete Paraplegia/quadriplegia; Spinal Cord Injury; Brainstem Stroke; Amyotrophic Lateral Sclerosis; Bilateral Upper Limb Amputation

Summary: the clinical trial aims to evaluate the safety and efficacy of the minimally invasive, wireless brain-machine interface system (wrs) in enabling general brain control of external devices, such as a cursor and other assistive technologies, for paralyzed and amputee patients. wrs integrates a high-throughput, ultra-flexible neural electrode with an extremely small cross-sectional size-approximately one-hundredth the diameter of a human hair. moreover, the implantable component is fully embedded within the body, leaving no visible external traces.

the investigators' technology is designed to assist paralyzed and amputee patients in regaining certain physical functions, thereby improving participants' overall quality of life and daily convenience. the investigators hope to enable participants to achieve general control over external devices through neural signals in this clinical trial. this eliminates the need for manual manipulation to control devices such as a cursor or other assistive technologies, which can be operated solely through thought. such advancements will facilitate enhanced communication with loved ones, support the acquisition of new skills, and provide more accessible opportunities for entertainment.

Eligibility criteria:
inclusion criteria: * aged 18-80 years (inclusive), any gender. * diagnosed with spinal cord injury, brainstem stroke, amyotrophic lateral sclerosis, or other motor neuron diseases causing partial or complete paralysis, or bilateral upper limb amputation. * diagnosis stable for at least 6 months before screening, with the condition present for at least 1 year. * willing to follow the study protocol and attend all visits, with or without caregiver assistance. * informed consent signed by participant and/or caregiver, with full understanding of the trial's purpose. exclusion criteria: * previous implantation of metal objects or devices (except dental implants or non-impacting implants). * long-term use of anticoagulants/antiplatelets with insufficient cessation, or abnormal coagulation test results. * unable to tolerate anesthesia or surgery. * severe neurological disorders or brain injury leading to significant dysfunction. * scalp conditions that may impair wound healing. * acute or severe infections. * cognitive impairment or psychiatric disorders. * severe dysfunction of vital organs, malignancies, or autoimmune diseases. * life expectancy under 1 year. * drug or alcohol abuse. * pregnant, breastfeeding, or planning pregnancy during the study. * other conditions deemed unsuitable by the investigator.
heme iron polypeptide for iron deficiency anemia in chronic renal failure

Conditions: Anemia; Renal Failure

Summary: the purpose of this study is to determine if oral heme iron polypeptide is as effective as intravenous (iv) iron sucrose in the treatment of iron-deficiency anemia for patients with chronic kidney disease.

iron deficiency anemia is common in patients with pre-dialysis chronic kidney disease, and is associated with significant morbidity. conventional treatment with oral iron salts or iv iron formulations are costly and are associated with side effects. heme iron polypeptide is a newly available formulation of oral iron which can be administered orally, is well absorbed by uremic patients, and has potentially fewer side effects. comparison: iron deficient anemic patients will be randomized to either oral heme iron polypeptide or iv iron sucrose for six months.

Eligibility criteria:
inclusion criteria: * egfr \&lt; 30 ml/min * hb 90-110 g/l * age \&gt; 18 * not on renal replacement therapy * transferrin saturation \&lt; 20% or ferritin \&lt;100 mcg/l * b12 \& folate within reference range exclusion criteria: 1. iron overload (tsat \> 50% or ferritin \> 800 μg/l); 2. malignancy; recurrent gastro-intestinal bleeding, major surgery or infection within the last 3 months; 3. parenteral iron therapy, blood transfusion within the last 3 months; 4. pregnancy; 5. contraindication to any study medication and; 6. inability or refusal to give consent.

Keywords: randomized controlled trial (rct) prospective studies ferric oxide, saccharated peptides heme iron erythropoietin, recombinant ferritin transferrin treatment outcome
safety and effectiveness of peg-intron in hiv-infected patients

Conditions: HIV Infections

Summary: the purpose of this study is to see if it is effective to give peg-intron (peg-ifn) to hiv-infected patients who are not doing well with their current anti-hiv drug combination (haart).

at entry, patients undergo hiv genotypic/phenotypic analysis. patients continue their current antiretroviral regimen but are randomized to receive one of four doses of peg-ifn or peg-ifn placebo administered subcutaneously once per week until results of hiv genotyping/phenotyping are available (approximately 4 weeks). patients who respond with a 0.5 log or greater decrease in hiv rna at week 4 have optimized haart added to their ongoing peg-ifn regimen and are followed for 24 weeks in an observational study.

Eligibility criteria:
inclusion criteria patients may be eligible for this study if they: * have hiv levels of more than 2000 copies/ml. * have failed their current haart (had a significant increase in their hiv levels with haart). * have a cd4 cell count greater than 200 cells/microl. * have had more than 6 months of haart. * have been on their current haart for at least 6 weeks. * agree to use an effective method of birth control during the study. exclusion criteria patients will not be eligible for this study if they: * have a history of a serious mental disorder. * are allergic to interferons. * are pregnant or breast-feeding. * are taking certain medications such as ribavirin, hydroxyurea, and ganciclovir.

Keywords: interferon alfa-2b lymphocyte transformation cd4 lymphocyte count rna, viral virus inhibitors anti-hiv agents viral load
prospective randomized trial on radiation dose estimates of ct angiography in patients applying iterative image reconstruction techniques - the protection v study -

Conditions: Coronary Artery Disease

Summary: the objective of this study is to compare a standard coronary ct angiography scan protocol with conventional image reconstruction with a scan protocol using reduced tube current and a new image reconstruction algorithm. the investigators hypothesize that the image quality of the new scan protocol is not inferior, while radiation dose estimates are reduced by around 30%. secondary endpoints of the study include quantitative image quality parameters, prevalence of non-diagnostic studies, prevalence of coronary artery plaques and plaque characteristics (calcified, non-calcified, mixed) and prevalence of follow-up examinations.


Eligibility criteria:
inclusion criteria: 1. patients with an indication for a coronary ct angiography (planned evaluation of the coronary arteries) 2. signed informed consent 3. stable sinus rhythm 4. age \> 18 years exclusion criteria: 1. known allergy to contrast agents. 2. patients with known coronary artery disease 3. pregnancy 4. no stable sinus rhythm 5. coronary ct examinations not focussing on coronary arteries

Keywords: coronary artery disease coronary ct angiography radiation dose iterative image reconstruction detection
safety of single intravenous administration of s95010 in human healthy volunteers

Conditions: Cardiovascular Diseases

Summary: the purpose of the study is to assess, the safety and tolerability of single ascending doses of s 95010 and to assess the pharmacokinetics (pk) of s 95010.


Eligibility criteria:
inclusion criteria: * young healthy male subjects aged between 18 and 45 years (both inclusive) exclusion criteria: * any acute or chronic illness or clinically relevant findings such as livers,kidney, spleen, cardiovascular disease, eye disease in the selection/ inclusion visit examinations * any abnormal laboratory result on blood and urine samples taken during screening, judged clinically relevant by the investigator * history of liver dysfunction or total bilirubin or alt or ast or alp or γgt \> uln at selection * history of renal dysfunction or gfr \< 75ml/min/1.73 m2 (mdrd equation) at selection

Keywords: healthy volunteer antimir single ascending dose
effect of bgg492 on eeg in patients with photosensitive epilepsy

Conditions: Photosensitive Epilepsy

Summary: this study will evaluate the efficacy of bgg492 in reducing the sensitivity to flashing lights of patients with photosensitive epilepsy, using eeg as a readout.


Eligibility criteria:
inclusion criteria: * diagnosis of photosensitive epilepsy exclusion criteria: - inconsistent photoparoxysmal response when stimulated by photic stimulation other protocol-defined inclusion/exclusion criteria may apply.

Keywords: photosensitive epilepsy, photic stimulation, electroencephalogram
iluvien registry safety study

Conditions: Chronic Diabetic Macular Oedema Considered Insufficiently Responsive to Available Therapies

Summary: the study will include any patient treated with iluvien at designated sites in european countries where marketing authorization has been granted in order to obtain broader safety and usage information.


Eligibility criteria:
inclusion criteria: * any patient treated with iluvien under this protocol will be included in the study. exclusion criteria: * patients/guardians who are unable to understand and sign the informed consent will be excluded from the study. retrospective enrollment criteria patients treated with iluvien prior to study initiation may be included provided they satisfy the inclusion and exclusion criteria, where applicable, as well as, the following requirements: 1. the site is allowed to enroll a patient who was treated with iluvien no more than 36 months prior to bringing the patient in for their first study visit. 2. the eligible patient must meet the data requirements as specified in the protocol, i.e., baseline data collected within 7 days prior to treatment with iluvien and additional data subsequently collected approximately every 6 months thereafter until enrolment into the study. 3. the eligible patient must be enrolled at least one year prior to the planned end of the study.
a clinical trial of decitabine in relapsed or refractory t-lymphoblastic lymphoma

Conditions: T-lymphoblastic Lymphoma

Summary: to explore the safety, tolerability, and clinical effects of decitabine combined with second-line chemotherapy regimens for patients with relapsed or refractory t-lymphoblastic lymphoma.

this is a prospective, open，investigator initial clinical trial with a single arm, aimed to evaluate the safety, tolerability, and efficacy of decitabine combined with second-line chemotherapy regimens (codox-m/ivac) in relapsed or refractory t-lymphoblastic lymphoma. a total of 40 patients are planned to be enrolled into the study. patients with diagnosis of relapsed or refractory t-lymphoblastic lymphoma will be treated with decitabine plus codox-m/ivac. the primary end point is responder rate (rr) and time to progression (ttp), and the secondary end points include overall survival (os) and the median survival time (mst).

Eligibility criteria:
inclusion criteria: * age: 14\~60 years; ecog rate ≤ 2; expected survival \> 3 months; * patients with t-lymphoblastic lymphoma diagnosed by histopathology detection; * patients ever received chemotherapy and/or radiotherapy;and can not be transplanted hematopoietic stem cells; * patients with no chemotherapy contraindications: hemoglobin ≥ 90 g/l, absolute neutrophil count ≥1.5 x 109/l, blood platelet ≥100 x 109/l, alt and ast ≤ 2-fold upper normal limit, serum bilirubin ≤ 1.5-fold upper normal limit, serum creatinine ≤ 1.5-fold upper normal limit, serum albumin ≥ 30 g/l, normal serofibrinogen; * at least one measurable nidus; * no other severe diseases conflict with this project, cardiopulmonary function is basically normal; * the urine or blood pregnancy test of women in childbearing age must be negative in 7 days before follow-up visit; * applicable for follow-up visit; * no other antitumor adjoint therapy (including antitumor chinese medicine, immunotherapy and biotherapy), but double phosphate anti-bone transfer therapy and other symptomatic treatment are acceptable; * understanding this study and assigning informed consent. exclusion criteria: * rejecting providing blood preparation; * allergic to drug in this study and with metabolic block; * rejecting adopting reliable contraceptive method in pregnancy or lactation period; * uncontrolled internal medicine disease (including uncontrolled diabetes, severe incompetence cardiac, lung, liver and pancreas); * with severe infection; * with primary or secondary central nervous system tumor invasion; * with immunotherapy or radiotherapy contraindication; * ever suffered with malignant tumor; * having peripheral nervous system disorder or dysphrenia; * with no legal capacity, medical or ethical reasons affecting research proceeding; * participating other clinical trials simultaneously; * adopting other anti-tumor medicine excluding this research; * the researchers considering it inappropriate to participate in the study.

Keywords: decitabine rr ttp os mst